202 related articles for article (PubMed ID: 34266884)
1. Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin.
Ylösmäki E; Fusciello M; Martins B; Feola S; Hamdan F; Chiaro J; Ylösmäki L; Vaughan MJ; Viitala T; Kulkarni PS; Cerullo V
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266884
[TBL] [Abstract][Full Text] [Related]
2. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
3. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
[TBL] [Abstract][Full Text] [Related]
4. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.
Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H
PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942
[TBL] [Abstract][Full Text] [Related]
5. A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth.
Yuan S; Shi C; Lv Y; Wang T; Wang H; Han W
Cancer Biother Radiopharm; 2009 Oct; 24(5):607-13. PubMed ID: 19877891
[TBL] [Abstract][Full Text] [Related]
6. Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.
Ylösmäki E; Malorzo C; Capasso C; Honkasalo O; Fusciello M; Martins B; Ylösmäki L; Louna A; Feola S; Paavilainen H; Peltonen K; Hukkanen V; Viitala T; Cerullo V
Mol Ther; 2018 Sep; 26(9):2315-2325. PubMed ID: 30005865
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
8. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Potential of Neoantigen Vaccines: Harnessing Bacille Calmette-Guérin Cell-Wall-Based Nanoscale Adjuvants for Enhanced Cancer Immunotherapy.
Liu K; Peng J; Guo Y; Li Y; Qi X; Duan D; Li T; Li J; Niu Y; Han G; Zhao Y
ACS Nano; 2024 May; 18(18):11910-11920. PubMed ID: 38680054
[TBL] [Abstract][Full Text] [Related]
11. Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling.
Antonelli AC; Binyamin A; Hohl TM; Glickman MS; Redelman-Sidi G
Proc Natl Acad Sci U S A; 2020 Aug; 117(31):18627-18637. PubMed ID: 32680964
[TBL] [Abstract][Full Text] [Related]
12. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
13. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
15. Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors.
Du Y; Liu Y; Wang D; Bai H; Wang Z; He X; Zhang P; Tian J; Wang J
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217574
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer immunotherapy.
Raez LE; Fein S; Podack ER
Clin Med Res; 2005 Nov; 3(4):221-8. PubMed ID: 16303887
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis.
Mizushima T; Jiang G; Kawahara T; Li P; Han B; Inoue S; Ide H; Kato I; Jalalizadeh M; Miyagi E; Fukuda M; Reis LO; Miyamoto H
Mol Cancer Ther; 2020 Sep; 19(9):1930-1942. PubMed ID: 32737155
[TBL] [Abstract][Full Text] [Related]
18. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
Front Immunol; 2020; 11():615091. PubMed ID: 33584702
[TBL] [Abstract][Full Text] [Related]
19. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
[TBL] [Abstract][Full Text] [Related]
20. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
